User login

Join The Debate

Cast your vote and join the conversation.

Membership is free.

Get Started

You are here

Paul Howard

Paul Howard

Director of Health Policy, Manhattan Institute
Paul Howard is a senior fellow at the Manhattan Institute, director of health policy, and a member of Project FDA, an MI initiative. He is a contributor to The Apothecary, the Forbes blog on health care policy and entitlement reform, and a regular columnist for The Morning Consult.  Howard has written on a wide variety of medical-policy issues, including FDA reform, biopharmaceutical innovation, consumer-driven health care, and Medicare and Medicaid reform. He is a co-author of the forthcoming book, Unlocking Precision Medicine (Encounter Books, 2016). He is often quoted on health care issues, and his work has appeared in such publications as Bloomberg View, Wall Street Journal, National Affairs, USA Today, RealClearPolitics, New York Post, Investor’s Business Daily, Health Affairs, and  He joined MI in 2000, as deputy director of its Center for Legal Policy, where he edited research papers, managed legal policy analyses, and organized conferences.

More About Paul Howard

Proposals to control drug prices may have populist appeal, but they miss the mark by ignoring the root cause of high health care costs—poor health—and the relatively modest role that medicines play in U.S. health care spending.

Rather than micromanage drug prices, Congress should focus on ways to let better drugs reach more patients in less time. More effective drugs reaching patients faster means better patient outcomes, and more competition, keeping drug prices in check.

Wednesday, October 21, 2015

Price control advocates argue that curtailing profits in the pharmaceutical industry would save the country money without reducing innovation. There is, however, no such thing as a free lunch. Bureaucratic price manipulation would only hurt the sickest patients.

Wednesday, September 23, 2015

Innovation is an expensive business, and we should do all we can to make drug development more efficient and predictable. More treatments and more cures would also lead to more competition based on price and value.

Wednesday, May 20, 2015
The natural question to ask is why the FDA shouldn’t just approve a product already approved for the European Union, Canada, and Australia, while monitoring the vaccine through postmarket surveillance records?
Sunday, February 14, 2016

When it comes to drug pricing, as in so much of our economy, the market is not the problem but the solution.

Monday, February 2, 2015
Paul Howard responds to Dr. Ezekiel Emanuel’s op-ed in the New York Times on the growing shortage of generic cancer drugs.
Wednesday, August 17, 2011